Journal of Visualized Experiments

Rapid, seamless generation of recombinant poxviruses using host-range and visual selection

--Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE61049R2
Full Title:	Rapid, seamless generation of recombinant poxviruses using host-range and visual selection
Section/Category:	JoVE Immunology and Infection
Keywords:	vaccinia virus; recombination; poxvirus; host range; protein kinase R; PKR; E3L
Corresponding Author:	Stefan Rothenburg UNITED STATES
Corresponding Author's Institution:	
Corresponding Author E-Mail:	sr1hsv@ksu.edu;rothenburg@ucdavis.edu
Order of Authors:	Stefan Rothenburg
	Sameera Vipat
	Greg Brennan
	Chorong Park
	Sherry L. Haller
Additional Information:	
Question	**Response**
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US$2,400)
Please indicate the **city, state/province, and country** where this article will be **filmed**. Please do not use abbreviations.	Davis, CA USA

TITLE:

Rapid, Seamless Generation of Recombinant Poxviruses using Host Range and Visual Selection

AUTHORS AND AFFILIATIONS:

Sameera Vipat[1*], Greg Brennan[1*], Chorong Park[1], Sherry L. Haller[2] Stefan Rothenburg[1†]

[1]School of Medicine, University of California Davis, Department of Medial Microbiology and Immunology, Davis, CA

[2]University of Texas Medical Branch at Galveston, Department of Microbiology and Immunology, Galveston, TX

*Authors contributed equally to the work

Email addresses of co-authors:

Sameera Vipat (sameera.vipat@gmail.com)
Greg Brennan (gbrennan@ucdavis.edu)
Chorong Park (chopark@ucdavis.edu)
Sherry L. Haller (shhaller@utmb.edu)

Corresponding author:
Stefan Rothenburg (rothenburg@ucdavis.edu)

KEYWORDS:

Vaccinia virus, Recombination, Poxvirus, Host range, Protein kinase R, E3L-mCherry

SUMMARY:

This is a method to generate “scarless” recombinant vaccinia viruses using host-range selection and visual identification of recombinant viruses.

ABSTRACT:

Vaccinia virus (VACV) was instrumental in eradicating variola virus (VARV), the causative agent of smallpox, from nature. Since its first use as a vaccine, VACV has been developed as a vector for therapeutic vaccines and as an oncolytic virus. These applications take advantage of VACV’s easily manipulated genome and broad host range as an outstanding platform to generate recombinant viruses with a variety of therapeutic applications. Several methods have been developed to generate recombinant VACV, including marker selection methods and transient dominant selection. Here, we present a refinement of a host range selection method coupled with visual identification of recombinant viruses. Our method takes advantage of selective pressure generated by the host antiviral protein kinase R (PKR) coupled with a fluorescent fusion gene expressing mCherry-tagged E3L, one of two VACV PKR antagonists. The cassette, including the gene of interest and the mCherry-E3L fusion is flanked by sequences derived from the VACV genome. Between the gene of interest and mCherry-E3L is a smaller region that is identical to the first ~150 nucleotides of the 3’ arm, to promote homologous recombination and loss of the mCherry-E3L gene after selection. We demonstrate that this method permits efficient, seamless

generation of rVACV in a variety of cell types without requiring drug selection or extensive screening for mutant viruses.

INTRODUCTION:

Vaccinia virus (VACV) was instrumental for the first successful eradication of a human pathogen, variola virus (VARV), from nature. Ever since the extermination of variola virus, poxviruses including VACV have continued to be useful therapeutic viruses for both human and animal medicine. For example, a VACV-based rabies virus vaccine has been very effective in preventing transmission of sylvatic rabies in Europe[1] and the United States[2]. More recently, recombinant poxviruses expressing a variety of anti-tumor molecules (e.g., single-chain antibodies or human erythropoietin) have seen encouraging success as oncolytic agents[3–5]. VACV is particularly attractive as a vector because it is readily amenable to genetic manipulation, possesses a broad host range, and it is stable under a variety of conditions, allowing easy transportation and vaccine viability in the field[6,7]. While multiple techniques have been developed to generate recombinant VACV for laboratory experiments and vaccine generation, current strategies to generate these viruses have notable limitations.

Because of the utility of VACV, multiple strategies to generate recombinant viruses have been developed. The first strategy employs homologous recombination to introduce a cassette including the transgene and a selectable marker gene such as an antibiotic resistance gene. The cassette is flanked by two ~500 nucleotides (nt) or larger arms directing the gene to a specific site in the viral genome, which is then stably integrated by double crossover events[8–10]. This strategy is rapid and efficient; however, it results in extra genetic material in the form of the marker gene that may produce unexpected effects. Furthermore, there is a practical upper limit to the number of transgenes that can be introduced limited by the number of unique selectable markers available. Transient dominant selection (TDS) strategies have addressed this issue by facilitating the generation of "scarless" recombinant viruses[11]. Using this strategy, a plasmid containing a mutant VACV gene and a selectable marker gene are integrated into the viral genome, but without additional flanking VACV DNA. This approach results in transient integration of the entire plasmid and duplication of the VACV gene as a result of integration by a single crossover event. This intermediate is stable as long as it is maintained under selection pressure, permitting enrichment of this construct. When selection is removed, the VACV duplication enables a second crossover event that results in the removal of the plasmid and subsequent formation of either the wild type (wt) or recombinant virus in an approximate 50:50 ratio. While TDS generates recombinant viruses without requiring the stable introduction of foreign DNA, multiple virus clones must be screened for the expected mutation by sequencing analysis, a potentially time consuming and costly step.

Here, we present an approach to generating recombinant poxviruses combining the best aspects of each of these approaches, similar to an approach that has been described for the replication incompetent modified vaccinia Ankara[12–14]. This strategy combines visual and host range selection to rapidly generate recombinant viruses by double crossover events, and subsequently eliminate the selectable marker gene by homologous recombination. This approach permits the rapid generation of mutants mediated by homologous recombination, with the "scarless" nature

of TDS approaches, while not requiring a subsequent screening step to distinguish wild type and mutant viruses. Our method also uses host range selection in place of antibiotic selection, eliminating the risk of chemically induced phenotypic changes in the cell line. For this approach, we have chosen to use the host antiviral protein kinase R (PKR) as the selective agent to generate recombinant VACV. PKR is expressed as an inactive monomer in most cell types[15]. Upon binding double-stranded RNA (dsRNA) at the N-terminal dsRNA-binding domains, PKR dimerizes and is autophosphorylated[16]. This active form of PKR phosphorylates the alpha subunit of the eukaryotic initiation factor 2 (eIF2), ultimately inhibiting delivery of initiator methionyl-tRNA to the ribosome, thereby preventing intracellular translation and broadly inhibiting the replication of many virus families[17,18].

In response to the broad and potent antiviral activity of PKR, many viruses have evolved at least one strategy to prevent PKR activation. Most poxviruses express two PKR antagonists, encoded by the E3L and K3L genes in VACV, which antagonize PKR through two distinct mechanisms[19]. E3 prevents PKR homodimerization by binding double-stranded RNA[20,21], while K3 acts as a pseudosubstrate inhibitor by binding directly to activated PKR and thereby inhibiting interaction with its substrate eIF2α[22]. Importantly, these two PKR antagonists do not necessarily inhibit PKR from all species. For example, the K3 homolog from the sheeppox virus strongly inhibited PKR from sheep, whereas the sheeppox E3 homolog did not show considerable PKR inhibition[23,24]. In this study, we present a method to use PKR-mediated selective pressure combined with fluorescence selection to generate a VACV recombinant deleted for E3L and K3L (VC-R4), which cannot replicate in PKR competent cells derived from diverse species. This recombinant virus provides an excellent background for rapid generation of recombinant viruses expressing genes under control of the native E3L promoter.

PROTOCOL:

1. Generating the recombination vector

1.1. Design primers to generate the selection cassette. Design each individual amplicon with overlapping sequences with neighboring amplicons and the vector to facilitate isothermal enzymatic assembly of DNA molecules, also called Gibson assembly, using any of several online primer design tools.

NOTE: This protocol can also be completed using traditional restriction endonuclease-based cloning methods. In that case, design primers with the appropriate restriction sites rather than with overlapping sequences.

1.2. Using the primers designed in step 1.1, PCR amplify the following elements in order from 5' to 3' (**Figure 1**): ~500 nucleotides of the VACV genomic region 5' of E3L (5' arm), EGFP or the gene of interest, ~150 nucleotides from the VACV genomic region immediately 3' of E3L (short 3' arm), a synthetic early/late poxvirus promoter[25], the mCherry-E3L fusion gene, and ~500 nucleotides from the VACV genomic region 3' of E3L including the short 3' arm (long 3' arm).

1.2.1. In a PCR tube, add the reagents in the following order for each amplicon: 17 µL of DNase free water, 1.2 µL of each primer (initial concentration = 10 µM, final concentration = 0.5 µM), 5 µL of 5x PCR reaction buffer, template DNA (10 ng for amplicons amplified from plasmids: EGFP and E/L promoter-mCherry-E3L cassette; 100 ng for amplicons amplified from viral genomic DNA: 5' and 3' arms), and 0.5 µL of DNA polymerase. Adjust the volume of water added for a final reaction volume of 50 µL.

NOTE: The concentration of template DNA should be empirically determined, but we generally start with 10 ng/reaction.

1.2.2. Place the tube(s) in a thermocycler, and melt the DNA at 98 °C for 30 s, and then use 25 rounds of a three-step PCR protocol: 98 °C for 5 s, 55 °C for 10 s, and 72 °C for 1 min.

NOTE: Determine the melting temperature based on the manufacturer's suggested Tm for each primer set. Determine the appropriate extension time based on the length of each amplicon (1 minute/kb).

1.3. Visualize the amplification products on a 1% agarose gel. Add 10 µL of each DNA product and 2 µL of loading buffer to each well, and run at 8 V/cm for 1 h.

1.4. Gel purify each amplicon using a DNA gel extraction kit and manufacturer's protocol. Elute the amplicons from the column by adding 50 µL of DNase free water and immediately centrifuging.

1.5. Linearize the pUC19 cloning vector using *EcoRI* endonuclease digestion. To a tube, add 1 µg of pUC19, water to a volume of 17 µL, 2 L of reaction buffer, and 1 µL (20 units) of *EcoRI*. Incubate at 37 °C for 1 h.

1.5.1. Visualize the amplification products on a 1% agarose gel run at 8 V/cm for 1 h. Excise the band from the gel, and purify the product using the DNA gel extraction kit as described in step 1.4.

1.6. Ligate all of the individual, gel purified amplicons and the linearized vector using a master mix kit.

1.6.1. To a PCR tube, add 0.2 pmol of linearized pUC19 and each amplicon (5' arm, EGFP, short 3' arm, E/L promoter-mCherry-E3L cassette, 3'arm). Add DNase free water to a final volume of 10 µL, and then add 10 µL of DNA assembly master mix. Incubate samples at 50 °C for 1 h.

1.7. Transform chemically competent *E. coli* with 2 µL of the assembled product from step 1.6 as previously described[26,27]. Plate 100 µL of the transformed cells on LB agarose plates containing 100 µg/mL ampicillin. Incubate the plates overnight at 37 °C.

1.8. Pick well-isolated colonies and transfer individual colonies to tubes containing Luria broth with 100 μg/mL ampicillin. Incubate the tubes overnight at 37 °C while shaking at 225 rpm.

1.9. Isolate the plasmids from the overnight culture using a plasmid miniprep kit. Check the concentration and purity of the DNA using a spectrophotometer. An A260/A280 ratio between 1.8 and 2.0 is acceptable.

1.10. Submit the plasmids for Sanger sequencing to determine whether the desired cloning product is correct. Store the DNA at -20 °C.

2. Generating the recombinant virus

2.1. Infect a confluent monolayer of suitable cells with the virus to be recombined at a multiplicity of infection of 1.0 (MOI = 1.0) in a 6-well plate. Incubate the infected cells at 37 °C and 5% CO_2 for 1 h. Then aspirate the medium and replace it with fresh DMEM. Incubate the infected cells at 37 °C and 5% CO_2.

NOTE: For replication competent viruses such as a vaccinia virus that lacks K3L[22], a cell line such as European rabbit kidney cell line RK13 (ATCC #CCL-37) or BSC-40 is appropriate. However, for replication deficient viruses, such as the virus described in this paper lacking both PKR antagonists E3L and K3L, a complementing cell line expressing these two genes in *trans* or PKR knock-down or knock-out cells are required.

2.2. Transfect the infected cells with 500 ng of the vector generated and validated in step 1.10 using a commercially available transfection reagent following the manufacturer's protocol. Incubate the cells at 37 °C and 5% CO_2 for 48 h.

NOTE: If using a vaccinia virus lacking both E3L and K3L, PKR-mediated selective pressure will drive selection of recombined viruses and maintain expression of the mCherry-E3L fusion protein in these cells. If desired, it should also be possible to PCR amplify only the insert to use for transfection instead of the whole plasmid.

2.3. 48 hours post-infection, harvest the infected monolayer. In some cases, the cells can be harvested by pipetting, but if they are still tightly adhered, harvest them with a cell scraper. Freeze-thaw the cells three times, and then sonicate the lysates for 15 s at 50% amplitude. Store this lysate at -80 °C until ready to use.

2.4. Serially 10-fold dilute the lysate harvested in step 2.3 from 10^{-1} to 10^{-6} by adding 120 μL of the lysate to 1080 μL of DMEM (10^{-1}), and then adding 120 μL of this dilution to 1080 μL of DMEM (10^{-2}), and repeating this process four more times. Add 1 mL of each dilution to an individual, confluent well of a PKR competent cell line, in this case RK13 cells.

2.4.1. Incubate the infected cells at 37 °C and 5% CO_2 for 1 h. Then aspirate the medium and replace it with fresh DMEM Incubate the infected cells at 37 °C and 5% CO_2.

2.5. 24 to 48 hours post-infection, identify recombinant viruses by fluorescence microscopy. Plaques from recombinant viruses express red fluorescence due to integration the mCherry-E3L fusion gene (**Figure 2**). If a virus devoid of PKR inhibitors was used initially, all plaques will contain recombinant virus.

2.6. Plaque purify recombinant viruses three times on RK13 cells. After the final round of plaque purification, all plaques should express red fluorescence.

2.7. Infect a confluent 6-well plate of RK13 cells expressing the VACV PKR inhibitors E3L and K3L (RK13+E3L+K3L cells[28]) with the plaque-purified red fluorescing virus from step 2.6. Aim for approximately 50-100 plaques per well.

NOTE: These cells provide the VACV PKR antagonists in trans and alleviate the PKR-mediated selective pressure to maintain the mCherry-E3L fusion gene, thus promoting "scarless" generation of the recombinant virus.

2.8. Identify collapsed viruses by fluorescence microscopy using an EVOS2 microscope, and a GFP filter cube (Excitation: 470/22, Emission: 525/50) and a RFP filter cube (Excitation: 531/40, Emission: 593/40).

NOTE: The frequency at which the mCherry-E3L fusion gene is lost is approximately 2.5% (**Table 2**). If EGFP is not included as a marker gene, plaques from mutant viruses that have lost the mCherry-E3L fusion gene will be colorless.

2.9. Plaque purify green-only (VC-R4) or colorless plaques (E3L) three times on RK13+E3L+K3L cells. Ensure that no plaques fluoresce red.

2.10. Confirm the loss of mCherry-E3L and the presence of the expected mutation by PCR and Sanger sequencing.

NOTE: If the gene or mutation of interest does not have PKR inhibitory activity, recombinant viruses must be grown on RK13+E3L+K3L cells or an equivalent PKR-inhibited or PKR deficient cell line (**Figure 3**).

REPRESENTATIVE RESULTS:

We used the procedure diagrammed in **Figure 1** to generate a VACV lacking both PKR antagonists E3L and K3L, by replacing E3L with EGFP in a virus already deleted for K3L (vP872). **Figure 2** shows red fluorescent plaques in PKR competent RK13 cells indicative of viral expression of mCherry-E3L, as well as EGFP expressed in RK13+E3L+K3L cells confirming the loss of E3L and collapse of the mCherry-E3L selection marker. **Figure 3** confirms that this recombinant virus, VC-R4, lacking both PKR antagonists cannot replicate in PKR competent RK13 cells, while the parent virus, vP872 expressing E3L, is replication competent. To confirm that this inability to replicate in RK13 cells was only due to the loss of E3L, we replaced EGFP in VC-R4 with E3L, to generate a revertant virus

using the same selection protocol. **Figure 3** also validates that this revertant virus replicates as efficiently as vP872 in RK13 cells. Interestingly, colorless plaques consistent with collapse of the mCherry-E3L selection marker were identified prior to selection in RK13+E3+K3 cells that are generally required to select "scarless" recombinants, likely because of the extended sequence identity between the mCherry-E3L recombination cassette and the E3L gene being inserted into VC-R4. Therefore, to determine the efficiency of recombination and the rate of collapse we elected to produce viruses expressing the poxvirus PKR antagonist K3L to avoid the problem of early collapse[23]. **Figure 4** indicates the appearance of colorless plaques (arrowheads) after infection of RK13+E3L+K3L cells. **Table 1** shows the results of three independent experiments, where on average 12.6% of progeny virions had undergone recombination with the transfected plasmid, similar to previously reported frequencies[29–31]. **Table 2** details the frequency of colorless plaques relative to total plaques in RK13+E3L+K3L cells, demonstrating the rate of collapse and loss of the mCherry-E3L selection marker occurred at a frequency of approximately 1.8%.

FIGURE AND TABLE LEGENDS:

Figure 1. Diagram of p837-GOI-mCherry-E3L as well as the host-range and visual recombination strategy. (**A**) 5' arm (black) and 3' arm (grey) flank the E3L locus (brown) in VACV. (**B**) In p837-GOI-mCherry-E3L, these arms flank a cassette containing the gene of interest (GOI), in this case EGFP, (green) separated from an mCherry-E3L (red) fusion gene under control of the synthetic early/late poxvirus promoter[25] blue) by a short 3' arm (grey). These external arms drive homologous recombination between VACV and the p837-GOI-mCherry-E3L. Black arrowheads indicate the sites of the overlapping primers used to generate this plasmid by Gibson cloning. (**C**) When PKR selective pressure is removed, viruses that have undergone intramolecular recombination between the short and long 3' arms can be selected. (**D**) Resulting in a virus (VC-R4) containing only the gene of interest in the E3L locus.

Figure 2. Fluorescent micrographs of (top) a recombinant virus plaque 24 hours after recombination with p837-GOI-mCherry-E3L expressing both mCherry (left) and EGFP (right) in RK13 cells. (Bottom) Micrograph of a recombinant virus plaque 48 hours after PKR-mediated selective pressure has been removed in RK13++ cells, expressing EGFP (right) but not mCherry (left). The scale bar indicates 650 μm for all panels.

Figure 3. VC-R4 cannot replicate in PKR competent cells. The indicated cell lines were infected with vP872 (blue), VC-R4 (green), or VC-R4+E3L (magenta) at MOI = 0.1. 48 hours post-infection the infected cells were harvested and titered by serial dilution on RK13+E3L+K3L cells. Titers are reported in PFU/mL, errors bars represent the standard deviation of three replicate experiments.

Figure 4. Loss of mCherry-E3L expression in RK13+E3L+K3L cells. Overlay of fluorescent and phase contrast micrographs of VC-R4+K3L-mCherry-E3L infected RK13+E3L+K3L cells. Three plaques no longer express mCherry (circles) due to collapse of the selection cassette yielding VC-R4+K3L.

Table 1. Recombination frequency of VACV with the p837-K3L-mCherry-E3L plasmid.

Table 2. Frequency of mCherry-E3L loss from VC-R4+K3L-mCherry-E3L in RK13+E3+K3 cells.

DISCUSSION:

Here we present a variation of a transient marker selection strategy [32] to generate recombinant vaccinia viruses without retaining foreign DNA in the final recombinant virus. Our strategy uses selective pressure mediated by the host antiviral protein PKR rather than other forms of selective pressure such as antibiotics. The use of host antiviral genes eliminates the possibility of chemically induced phenotypic changes in the cells, or increased risk of mutation due to selection drugs. Furthermore, unlike with drug selection, there is no lag phase for our approach, because PKR is expressed constitutively in all cells. Secondary visual selection based on mCherry expression also improves the specificity of this method by ensuring that only plaques expressing the transgene are picked during the first phase, and is equally efficient as a negative selective marker while selecting mature recombinant viruses that have lost the mCherry-E3L gene.

The most critical steps for this recombination strategy are the generation of the appropriate recombination vector, and appropriate plaque purification to ensure that the selected virus is clonal. In this paper we suggest "Gibson assembly" to generate the recombination vector. This strategy is extremely efficient and allows assembly of all the fragments comprising the recombination vector in a single day. However, because the short 3' arm and the long 3' arm share identical sequences, these fragments have the potential to be joined together during the cloning reaction, and some vectors may not contain the mCherry-E3L cassette. In our experience this is rare but confirming the structure of the vector after cloning is necessary. We have also generated recombination vectors for this strategy using traditional endonuclease and ligase methods. This strategy avoids the problem described above but can be more labor intensive. Plaque purification is generally straightforward and is primarily reliant on using appropriate permissive cells for the initial recombination, PKR-competent cells for initial plaque purification to ensure that only recombinant viruses can replicate, and then permissive cells again to facilitate intramolecular recombination and loss of the selectable marker. Close attention to cell lines is therefore critical for the successful and efficient application of this strategy.

In this study, we demonstrate the use of this method to generate a VACV recombinant deleted for both PKR antagonists E3L and K3L and expressing EGFP under control of the E3L promoter. Going forward, this virus will serve as an efficient background for future recombinant viruses, as it is incapable of replicating in PKR competent cells. Therefore, there will be strong PKR-mediated selective pressure to drive the mCherry-E3L recombination cassette into progeny virions while at the same time essentially preventing replication of non-recombinant virus. Furthermore, the loss of EGFP by uptake of the recombination cassette is a useful secondary selection marker to ensure picked plaques are not co-infected with a non-recombinant virus. We observed rates of recombination consistent with previously reported rates for VACV, but the visual fluorescent markers increase the efficiency of generating recombinant viruses by ensuring that increasing the likelihood that the appropriate recombinant viruses are selected. Our observation of colorless plaques after two rounds of selection on PKR-competent cells, presumably due to the increased length of identical sequence between E3L and the mCherry-E3L marker gene, suggests that the rate of mCherry-E3L loss may be "tuned" by increasing or decreasing the length of the

3’ short arm. The primary limitation of this technique is the use of PKR as the selective pressure for recombinants. The most efficient use of this recombination strategy is generating these viruses in a background lacking PKR antagonists. However, the colorimetric selection marker allows this recombination strategy to be used even without the selection mediated by PKR, simply by plaque purifying mCherry-expressing plaques. While the lack of PKR-mediated selective pressure will reduce the efficiency of the first screening step, the percentage of mCherry expressing plaques is still high enough that color-based selection is viable. Thus, this method can be used to insert nearly any gene into the poxvirus genome.

As demonstrated by the insertion of EGFP, with this approach, any gene can be rapidly inserted into the E3L locus under control of the native promoter, provided that PKR null cells or complimenting cell lines are used for downstream experiments if the transgene is not a PKR antagonist. This strategy, combined with the VC-R4 virus that we report here, adds a new and potent method to rapidly and reliably generate recombinant vaccinia viruses using host-mediated selective pressure and visual identification of recombinants early in the process.

ACKNOWLEDGMENTS:
This project was funded by the National Institutes of Health (AI114851) to SR.

DISCLOSURES:
The authors declare no competing financial interests.

REFERENCES:
1. Brochier, B. et al. Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine. *Nature*. **354** (6354), 520–522 (1991).
2. Pastoret, P.P., Brochier, B. The development and use of a vaccinia-rabies recombinant oral vaccine for the control of wildlife rabies; a link between Jenner and Pasteur. *Epidemiology and Infection*. **116** (3), 235–40 (1996).
3. Chan, W.M., McFadden, G. Oncolytic Poxviruses. *Annual review of virology*. **1** (1), 119–141 (2014).
4. Nguyen, D.H. et al. Vaccinia virus-mediated expression of human erythropoietin in tumors enhances virotherapy and alleviates cancer-related anemia in mice. *Molecular Therapy*. **21** (11), 2054–62 (2013).
5. Frentzen, A. et al. Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. *Proceedings of the National Academy of Sciences of the United States of America*. **106** (31), 12915–20 (2009).
6. Pastoret, P.-P., Vanderplasschen, A. Poxviruses as vaccine vectors. *Comparative Immunology, Microbiology and Infectious Diseases*. **26** (5–6), 343–355 (2003).
7. COLLIER, L.H. The development of a stable smallpox vaccine. *The Journal of Hygiene*. **53** (1), 76–101 (1955).
8. Weir, J.P., Bajszár, G., Moss, B. Mapping of the vaccinia virus thymidine kinase gene by marker rescue and by cell-free translation of selected mRNA. *Proceedings of the National Academy of Sciences of the United States of America*. **79** (4), 1210–4 (1982).
9. Mackett, M., Smith, G.L., Moss, B. Vaccinia virus: a selectable eukaryotic cloning and

expression vector. *Proceedings of the National Academy of Sciences of the United States of America.* **79** (23), 7415-7419 (1982).
10. Nakano, E., Panicali, D., Paoletti, E. Molecular genetics of vaccinia virus: demonstration of marker rescue. *Proceedings of the National Academy of Sciences of the United States of America*. **79** (5), 1593–6 (1982).
11. Falkner, F.G., Moss, B. Transient dominant selection of recombinant vaccinia viruses. *Journal of Virology*. **64** (6), 3108–3111 (1990).
12. Staib, C., Drexler, I., Ohlmann, M., Wintersperger, S., Erfle, V., Sutter, G. Transient Host Range Selection for Genetic Engineering of Modified Vaccinia Virus Ankara. *BioTechniques*. **28** (6), 1137–1148 (2000).
13. Staib, C., Drexler, I., Sutter, G. Construction and Isolation of Recombinant MVA. *Vaccinia Virus and Poxvirology*. 77–99 (2004).
14. Di Lullo, G. et al. Marker gene swapping facilitates recombinant Modified Vaccinia Virus Ankara production by host-range selection. *Journal of Virological Methods*. **156** (1–2), 37–43 (2009).
15. Pfaller, C.K., Li, Z., George, C.X., Samuel, C.E. Protein kinase PKR and RNA adenosine deaminase ADAR1: New roles for old players as modulators of the interferon response. *Current Opinion in Immunology*. **23** (5), 573-582(2011).
16. Bevilacqua, P.C., George, C.X., Samuel, C.E., Cech, T.R. Binding of the protein kinase PKR to RNAs with secondary structure defects: Role of the tandem A - G mismatch and noncontigous helixes. *Biochemistry*. **37** (18), 6303-6316 (1998).
17. Krishnamoorthy, T., Pavitt, G.D., Zhang, F., Dever, T.E., Hinnebusch, A.G. Tight Binding of the Phosphorylated Subunit of Initiation Factor 2 (eIF2) to the Regulatory Subunits of Guanine Nucleotide Exchange Factor eIF2B Is Required for Inhibition of Translation Initiation. *Molecular and Cellular Biology*. **21** (15), 5018–5030 (2001).
18. Rothenburg, S., Georgiadis, M.M., Wek, R.C. Evolution of eIF2α kinases: Adapting translational control to diverse stresses. *Evolution of the Protein Synthesis Machinery and Its Regulation*. 235–260 (2016).
19. Bratke, K.A., McLysaght, A., Rothenburg, S. A survey of host range genes in poxvirus genomes. *Infection, Genetics and Evolution*. **14**, 406-425 (2013).
20. Chang, H.W., Watson, J.C., Jacobs, B.L. The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase. *Proceedings of the National Academy of Sciences*. **89** (11) 4825-4829 (1992).
21. Romano, P.R. et al. Inhibition of double-stranded RNA-dependent protein kinase PKR by vaccinia virus E3: role of complex formation and the E3 N-terminal domain. *Molecular and Cellular Biology*. **18** (12), 7304-7316 (1998).
22. Beattie, E., Tartaglia, J., Paoletti, E. Vaccinia virus-encoded eIF-2 alpha homolog abrogates the antiviral effect of interferon. *Virology*. **183** (1), 419–422 (1991).
23. Park, C., Peng, C., Brennan, G., Rothenburg, S. Species-specific inhibition of antiviral protein kinase R by capripoxviruses and vaccinia virus. *Annals of the New York Academy of Sciences*. **1438** (1), 18–29 (2019).
24. Rothenburg, S., Brennan, G. Species-Specific Host–Virus Interactions: Implications for Viral Host Range and Virulence. *Trends in Microbiology*. (2019).
25. Chakrabarti, S., Sisler, J.R., Moss, B. Compact, synthetic, vaccinia virus early/late

promoter for protein expression. *BioTechniques*. **23** (6), 1094-1097 (1997).
26. Chung, C.T., Niemela, S.L., Miller, R.H. One-step preparation of competent Escherichia coli: Transformation and storage of bacterial cells in the same solution (recombinant DNA). *Biochemistry*. **86**, 2172–2175 (1989).
27. Chung, C.T., Miller, R.H. Preparation and storage of competent Escherichia coli cells. *Methods in Enzymology*. **218**, 621–627 (1993).
28. Rahman, M.M., Liu, J., Chan, W.M., Rothenburg, S., McFadden, G. Myxoma Virus Protein M029 Is a Dual Function Immunomodulator that Inhibits PKR and Also Conscripts RHA/DHX9 to Promote Expanded Host Tropism and Viral Replication. *PLOS Pathogens*. **9** (7), e1003465 (2013).
29. Evans, D.H., Stuart, D., McFadden, G. High levels of genetic recombination among cotransfected plasmid DNAs in poxvirus-infected mammalian cells. *Journal of Virology*. **62** (2), 367–75 (1988).
30. Ball, L.A. High-frequency homologous recombination in vaccinia virus DNA. *Journal of Virology*. **61** (6), 1788–95 (1987).
31. Spyropoulos, D.D., Roberts, B.E., Panicali, D.L., Cohen, L.K. Delineation of the viral products of recombination in vaccinia virus-infected cells. *Journal of Virology*. **62** (3), 1046–54 (1988).
32. Liu, L. et al. Transient dominant host-range selection using Chinese hamster ovary cells to generate marker-free recombinant viral vectors from vaccinia virus. *BioTechniques*. **62** (4), 183–187 (2017).

Figure 1



Figure 2



Figure 3



Figure 4

Click here to access/download;Figure;Fig. 4.pdf



Table 1

	Experiment 1	Experiment 2	Experiment 3
Red plaques (RK13)	30	11	18
Total plaques (RK13+E3L+K3L)	225	64	249
Recombination Rate	13.30%	17.20%	7.20%

Table 2

	Experiment 1	Experiment 2	Experiment 3
Total plaques (RK13+E3L+K3L)	115	44	210
Colorless plaques (RK13+E3L+K3L	3	1	1
Recombination Rate	2.60%	2.30%	0.50%

Name of Material/ Equipment	Company	Catalog Number	Comments/Description
2X-Q5 Master Mix	NEB	M0492L	High-fidelity polymerase used in PCR
Ampicillin	ThermoFisher Scientific	11593027	Bacterial selective agent
Disposable Cell Scrapers	ThermoFisher Scientific	08-100-242	Cell scraper to harvest infected cells
EVOS FL Auto 2 Cell imaging system	ThermoFisher Scientific	AMAFD2000	Fluorescent microscope
EVOS Light Cube, GFP	ThermoFisher	AMEP4651	GFP Cube
EVOS Light Cube, RFP	ThermoFisher	AMEP4652	RFP Cube
GenJet	SignaGen Laboratories	SL100489	Transfection reagent
Luria Bertani (LB) Broth	Gibco	10855021	Bacterial growth medium
Monarch DNA gel extraction kit	NEB	T1020L	Gel purification kit used to purify amplicons and
Monarch Plasmid Miniprep kit	NEB	T1010L	Miniprep kit ussed to purify plasmids
NanoDrop One	ThermoFisher Scientific	ND-ONE-W	Spectrophotometer used to measure RNA and
NEBuilder Master Mix	NEB	E2621L	Isothermal enzymatic assembly kit used to gene
Q500 Sonicator	Qsonica	Q500-110	Sonicator for virus lysates
RK13 cells	ATCC	CCL-37	Rabbit kidney cells
VWR Multiwell Cell Culture plates	VWR	10062-892	Cell culture plates

d linearized vectors

DNA concentration
erate the recombination vector

Response to Reviewers

We thank the reviewers for their time and constructive comments. In addition to the reviewer comments, during revision we found that we inadvertently colored Fig 2 incorrectly. Therefore, we have changed the top two panels to correct this error. The changes we made in response to the reviewer's suggestions are indicated below in italic text.

Protocol
Specific Protocol steps:
1. 1.1.9: How do you transform E. coli here?

We have inserted references 26 and 27 detailing our method.

Figures:
1. Figure 1: Panels are indicated in the legend, but not labeled in the figure itself.

We have revised the figure to include panel designations.

2. Figure 3: Please explain the error bars in the legend.

We have indicated that the error bars are standard deviations of three experiments.

Discussion:
1. Please revise the Discussion to explicitly cover the following in detail in 3–6 paragraphs with citations:
a) Critical steps within the protocol
b) Any limitations of the technique
c) The significance with respect to existing methods

We have added new text to the discussion and explicitly indicated each of these sections in the text.

References:
1. Please do not abbreviate journal titles.

We have fixed some of these abbreviations with a new citation format kindly provided by the journal. Our editor, Phillip Steindel, indicated that the rest could be corrected during the editing and typesetting process. Thank you.

2. Please resolve the inverted parentheses around issue numbers.

This has been corrected with the new citation format.

Table of Materials:
1. Please ensure the Table of Materials has information on all materials and equipment used, especially those mentioned in the Protocol.

All materials and equipment is in the Table of Materials.

Reviewer 1

Protocol step 1, "Generating the Recombination Vector," would it be ok to use PCR product directly for recombinant virus generation?
This would be difficult as cloning steps are necessary to generate the correct architecture. However, once generated in a plasmid, this is theoretically possible although we haven't tried this approach. We have indicated this in lines 190-1.

2. Protocol Step 2, "Generating the Recombinant Virus," it might help the reader to follow the protocol by separating better when using "RK13 (ATCC #CCL-37) or BS-C-40 cells with a vaccinia virus that lacks K3L or RK13+E3L+K3L cells, with a virus that lacks both E3L and K3L".

We have moved some of this to the NOTE section, and expanded the discussion of this protocol step to provide additional clarity.

3. This reviewer suggests using hours, instead of days, in the protocol.

We have made this change throughout the manuscript.

4. In the discussion, it would be helpful to discuss the limitation of this method.

We have included this in the discussion, beginning at line 341.

5. Fig. 3, please label Y-axis. Please change Hela to HeLa. -

We have corrected these oversights in Fig. 3.

Reviewer 2

Major Concerns:
Although the technique is relatively straightforward, the subject (PKR +E3L +K3L) is convoluted. An extra figure might help, as well as information whether this procedure is limited to knocking out these host range genes. How does it work with other genes? It really isn't very easy to follow what's going on.

We have added some sentences describing the selection of recombinants by colorimetric selection only, both the possibility and the limitations, in the discussion lines 342-351.

1) I would ask the authors to examine their use of "homology" and "homologous" throughout the text and see if it would be better to use some form of "similarity" or "identity". Homology has a specific meaning (https://sandwalk.blogspot.com/2012/01/margoliash-on-homology-1969.html), specifically related to shared ancestry. Phrases like "extended homology" and "increased homology" could be improved.

We have removed the term "homology" throughout the text, for example changing "homology arms" to "arms"

2) Line 77 +196 Both methods require sequencing, so why is this an advantage?

Transient dominant selection requires sequencing because it does not generate predominantly recombinant viruses and thus recombinants must be screened. This method should generate pure recombinant viruses, thus, sequencing is purely for prudence and not screening. Clarified in line 77.

3) Line 81 "VACV modified vaccinia Ankara" Not the usual way MVA is described.
We have deleted "VACV" and now only describe the virus as "modified vaccinia Ankara".

4) line 97 this nomenclature is from VACV-Copenhagen.

Correct, we use this nomenclature consistently throughout the text as our viruses are generated in this background.

5) line 102 referring twice to sheeppox. Something mixed up??

Line 102 discusses the phenotype of two distinct gene products from sheeppox, the homologs of E3 and K3. This is written as intended.

6) line 127 How much DNA template?

We have included this estimation in the text.

7) Line 109 A figure for 1.1.1 might help, or add more to Fig 1.

We have expanded Fig. 1 to provide clarity.

8) Line 227 p837 is referred to in the legends, but not the text. What's the relationship with 872?

There is no relation. Vp872 is a virus, and p837 is referring to a separate and unrelated plasmid.

9) line 235 "with a short, untranslated molecular tag". Isn't this supposed to be scarless?

Thank you, this sentence refers to a different virus and was inadvertently left in the text. We have deleted this description.

10) Fig 1. Some indication of DNA sizes would be helpful. Sections A, B, C, D need to be indicated.

We have included a scale bar and indicated the panels.

11) Fig 3. If the virus doesn't replicate in some cells, is the small amount of virus inoculum?

This is likely to be the case, however; we haven't formally tested this hypothesis.

12) Fig 4. Would a phase contrast picture help show the non-fluorescent plaques?

Figure 4 is an overlay of a red fluorescent image with a phase contrast image. However, at the 4x magnification necessary for this figure, resolving the cells is challenging in the context of a composite image and this was the best of several images. We have updated the figure legend to indicate that this image is an overlay.